Insulet Corporation (NASDAQ:PODD) Scheduled to Post Earnings on Thursday
Insulet Corporation (NASDAQ:PODD) will release its earnings data after the market closes on Thursday, August 3rd. Analysts expect Insulet Corporation to post earnings of ($0.13) per share for the quarter.
Insulet Corporation (NASDAQ:PODD) last released its earnings results on Monday, May 8th. The medical instruments supplier reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The firm had revenue of $101.70 million during the quarter, compared to analyst estimates of $97.73 million. Insulet Corporation had a negative net margin of 6.81% and a negative return on equity of 48.46%. Insulet Corporation’s quarterly revenue was up 25.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.19) EPS. On average, analysts expect Insulet Corporation to post $-0.48 EPS for the current fiscal year and $-0.14 EPS for the next fiscal year.
Insulet Corporation (NASDAQ PODD) traded down 1.39% during trading on Thursday, reaching $52.50. 118,865 shares of the company traded hands. Insulet Corporation has a 12-month low of $30.69 and a 12-month high of $53.90. The firm’s market capitalization is $3.04 billion. The firm’s 50 day moving average price is $49.04 and its 200 day moving average price is $44.30.
In related news, SVP Michael P. Spears acquired 2,500 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was purchased at an average cost of $40.59 per share, with a total value of $101,475.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David A. Lemoine sold 1,524 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $43.40, for a total transaction of $66,141.60. The disclosure for this sale can be found here. Insiders have bought 8,080 shares of company stock valued at $317,339 over the last three months. 1.90% of the stock is owned by corporate insiders.
PODD has been the topic of a number of research reports. Jefferies Group LLC reaffirmed a “buy” rating on shares of Insulet Corporation in a research note on Friday, June 16th. Canaccord Genuity reaffirmed a “hold” rating and set a $42.00 target price on shares of Insulet Corporation in a research note on Friday, May 26th. BidaskClub raised shares of Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Cowen and Company reaffirmed a “buy” rating and set a $52.00 target price on shares of Insulet Corporation in a research note on Friday, July 14th. Finally, ValuEngine raised shares of Insulet Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $48.15.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.